-
Supriya Lifescience announces the launch of its new Injectable Division
The Injectable Division will focus on developing, manufacturing, and marketing a wide range of injectable products, including antibiotics, anti-infectives, and pain management medications.
-
Supriya Lifescience receives US FDA approval for its new antibiotic drug
The drug, which is a broad-spectrum antibiotic, is indicated for the treatment of a variety of bacterial infections.
-
Supriya Lifescience partners with global healthcare company to distribute its products in emerging markets
The partnership will enable Supriya Lifescience to reach a wider patient population and expand its global footprint.
-
Supriya Lifescience Q3 net profit jumps 28.5%
Supriya Lifescience on Friday reported a 28.5 per cent rise in its consolidated net profit to Rs 62.49 crore for the third quarter ended December 2022.
-
Supriya Lifescience gets USFDA nod for generic drug
Supriya Lifescience on Tuesday said it has received final approval from the US health regulator for its generic drug Levetiracetam Injection.
-
Supriya Lifescience enters into strategic partnership with Zydus Lifesciences
Supriya Lifescience on Monday said it has entered into a strategic partnership with Zydus Lifesciences to market and distribute a range of branded generic products.
-
Supriya Lifescience Gets USFDA Nod for Generic Version of Skin Infection Drug
The generic version of Aczone Gel, 7.5% is used topically to treat mild to moderate inflammatory acne vulgaris in patients 12 years of age and older.
-
Supriya Lifescience Q3 net profit up 14% to Rs 122 crore
The company's revenue from operations grew by 13% to Rs 523 crore in the quarter ended December 2022, compared with Rs 462 crore in the corresponding period of the previous year.
-
Supriya Lifescience launches generic version of Actemra in India
The Actemra generic, Tocilizumab, is indicated for the treatment of rheumatoid arthritis in adults.
-
Supriya Lifescience Receives GMP Certificate for its Oncology API Facility
Supriya Lifescience Limited (SLL), a leading global manufacturer of active pharmaceutical ingredients (APIs), has received a Good Manufacturing Practices (GMP) certificate from the European Medicines Agency (EMA) for its oncology API manufacturing facility located in Panoli, Gujarat, India.
-
Supriya Lifescience Enters into Strategic Partnership with Syngene International
Supriya Lifescience Limited (SLL) has entered into a strategic partnership with Syngene International Limited, a leading global provider of integrated research, development, and manufacturing services for the pharmaceutical and biotechnology industries.
-
Supriya Lifescience Appoints Dr. C. S. Sethumadhavan as Non-Executive Director
Supriya Lifescience Limited (SLL) has appointed Dr. C. S. Sethumadhavan as an Independent Non-Executive Director to its Board of Directors, effective January 1, 2023.
-
Supriya Lifescience Q3 net profit rises 3% to Rs 22.15 crore
Supriya Lifescience on Thursday reported a 3 per cent rise in its consolidated net profit to Rs 22.15 crore for the quarter ended December 31, 2022.
-
Supriya Lifescience gets USFDA nod for generic version of heart drug
Supriya Lifescience on Wednesday said it has received the US health regulator's approval to market the generic version of heart drug, Ivabradine Hydrochloride.
-
Supriya Lifescience Q2 net profit jumps 19% to Rs 21 crore
Supriya Lifescience on Thursday reported a 19 per cent rise in its consolidated net profit to Rs 21 crore for the quarter ended September 30, 2022.
-
Supriya Lifescience announces partnership with US-based Reagents Direct
The partnership is aimed at providing a comprehensive suite of life science solutions to researchers and clinicians in North America. Supriya Lifescience will provide Reagents Direct with access to its portfolio of high-quality antibodies, proteins, and reagents, while Reagents Direct will offer its expertise in distribution and customer service.
-
Supriya Lifescience reports strong financial results for Q1 FY24
The company reported a 25% increase in revenue and a 30% increase in net profit for the quarter ended June 30, 2023. The growth was driven by strong demand for its products in both domestic and international markets.
-
Supriya Lifescience launches new range of products for cancer research
The new range of products includes antibodies, proteins, and reagents specifically designed for cancer research. The products are intended to help researchers better understand the mechanisms of cancer and develop new therapies.
